Crown Aesthetics reinforces its commitment to customer education and training
DALLAS, September 14, 2022 /PRNewswire/ — Crown Aesthetics (“Crown”), a division of Crown Laboratories, Inc., today announced that its UK and Ireland (“UKI”) team will now offer all Ireland SkinPen Precision customers have the opportunity to receive internationally recognized Continuing Professional Development (“CPD”) accreditation.
At the end of our Crown Educational Learning programme, all UK SkinPen customers of Crown and Ireland direct markets will receive CPD education points which will go towards their own self-development learning. This is the first CPD opportunity for aesthetic microneedling practices in these countries.
Crown’s SkinPen Precision self-paced training program includes 3 hours of online pre-learning modules and a 6-hour academy, virtual seminar, live seminar or in-clinic masterclass. The comprehensive Masterclass is interactive and aims to educate on the versatility and effectiveness of microneedling using SkinPen Precision in accordance with FDA and CE guidelines. Program content includes skin anatomy, diagnosis and wound healing responses, mechanism of action, clinical studies, FDA and CE approved protocols, contraindications and precautions, creating satisfied patients and adjustment of treatment.
Crown Aesthetics is built on three fundamental pillars: technology, education and customer service. Crown guarantees that SkinPen meets or exceeds all industry standards for efficacy and safety. Because we are very proud of our technology, it is essential that our aesthetic practices do the same. Because our customers continually seek to improve their skills and techniques, we are committed to providing them with opportunities to stay current with our latest innovations and to hone their skills. By investing in accredited CPD training to help our practices deliver our first micro-needling treatment to their patients, we are giving our practice partners a competitive advantage in growing their SkinPen patient base.
“Crown Aesthetics delivers on its commitment to its partner clinics by helping them succeed with our technologies,” said Angela Wilson McDonald, Senior Director of Global Education for Crown Aesthetics. “Through education and support, we help them achieve the highest level of safety and effectiveness for their patients. This is the foundation Crown Aesthetics was founded on in 2013 and has allowed us to emerge as a global leader in the skin reshaping market with SkinPen Precision.”
About Crown Aesthetics
Crown Aesthetics, the premier medical aesthetics company, is dedicated to helping leading practices around the world grow their business. We do this by providing dramatic results in rejuvenation and restoration. Our minimally invasive innovations – SkinPen®, the first FDA-approved micro-needling device; MicroPen EVO™, ProGen PRP™ Advantage and Eclipse PRP® platelet-rich plasma (PRP) systems, VOTESSE™, a hair health system; and the Skinfuse® post-microneedling protocol – act as “gateway” products that drive new, highly satisfied patients into practices. Situated at Dallas, TX, Crown Aesthetics sets the industry standard for efficacy, safety and innovation. As a result, our clients consistently provide the best aesthetic care in the industry. For more information, please visit www.crownaesthetics.com.
About Crown Laboratories, Inc.
Crown, a fully integrated, privately owned, global skincare company, is committed to developing and delivering a diverse portfolio of aesthetic, premium and therapeutic skincare products that enhance the quality of life of its consumers while along their skincare journey. An innovative company focused on the science of skin for life, Crown’s unwavering pursuit to deliver therapeutic excellence and improved patient outcomes is why it has become a leader in dermatology and aesthetics. Crown has been on the Inc. 5000 list of fastest growing private companies for nine years and has expanded its distribution to more than 41 countries. For more information, visit www.crownlaboratories.com.
SOURCECrown Laboratories, Inc.